Intrathecal administration of AS-ODN of REST produces significant increase on expression of NR2B at 7 day after inoculation compared with the vehicle group, which reconfirms the reduced expression inhibition of spinal REST on NR2B during the progress of bone cancer pain. The gene discussed is GRIN2B; the disease is bone neoplasm.